CKD-701 vs Tarcocimab tedromer
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
CKD-701 · Lucenbies
Marketed by Chong Kun Dang Pharmaceutical
NCT04857177 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.
Reported efficacy
The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline. (Baseline to 3 months): Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). (met)
Result source: NCT04857177
Tarcocimab tedromer
Developed by Kodiak Sciences Inc.
NCT06556368 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)
Result source: NCT04964089
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. CKD-701: 0 of 4 rows · Tarcocimab tedromer: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | CKD-701 | Tarcocimab tedromer |
|---|---|---|
| Dropout rate | — | 8.3% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Discontinued due to AEs | — | 2.9% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | — | 14.1% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | — | covid-19 12.3% neovascular age-related macular degeneration - fellow eye 8% vitreous floaters - study eye 7.6% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
CKD-701
Tarcocimab tedromer
+ 68 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-701's landscape · Tarcocimab tedromer's landscape